True histiocytic lymphoma following therapy for lymphoblastic neoplasms

27Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

True histiocytic lymphomas (THLs) are rare tumors in which the malignant cells show morphologic and immunophenotypic evidence of histiocytic differentiation. We describe THLs that arose after therapy for one case of T- lineage lymphoblastic lymphoma (LyL) and two cases of acute lymphoblastic leukemia (ALL) (both CD10+, one pre-B phenotype). The lymphoblastic neoplasms were not unusual in any way, and responded well to standard therapy. The THLs arose 10 to 20 months after complete remission was achieved for the lymphoblastic neoplasms, at which time there was still no clinical or pathologic evidence of the lymphoblastic neoplasms. All three THLs exhibited clinical and morphologic features of malignancy. Neoplastic cells in the THLs had abundant eosinophilic vacuolated cytoplasm and pleomorphic nuclei, and expressed histiocytic antigens in the absence of lymphocyte-specific lineage markers. Because THLs are rare neoplasms, their occurrence after otherwise successful therapy for lymphoblastic neoplasms in these three cases may constitute a distinct clinicopathologic entity.

Cite

CITATION STYLE

APA

Soslow, R. A., Davis, R. E., Warnke, R. A., Cleary, M. L., & Kamel, O. W. (1996). True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood, 87(12), 5207–5212. https://doi.org/10.1182/blood.v87.12.5207.bloodjournal87125207

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free